Zynex Inc

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zynex Inc (ZYXI) achieves record highs in Q4 2022

Zynex Inc (ZYXI) delivered strong financial performance in Q4 2022 and full-year 2022, projecting continued growth in 2023. The company's focus on innovation, regulatory milestones, and operational efficiency positions it well for future success.

Zynex Inc reports robust Q1 earnings, eyes revenue growth

Zynex Inc's Q1 2023 performance reflects strong revenue growth and increased orders, supported by strategic initiatives like stock buybacks.
While facing challenges in scaling the sales force and navigating market dynamics, the company is well-positioned to leverage opportunities for expansion and innovation.
Investors can look forward to continued revenue growth, product development, and potential market expansion as Zynex pursues its growth targets.

Zynex Inc reports record revenue and FDA clearances, reaffirms guidance

Zynex Inc delivered robust financial results in Q2 2023, showcasing consistent profitability and revenue growth across its divisions.
The company's focus on product innovation, FDA clearances, and strategic financial moves underscores its commitment to sustained growth and market leadership.
While facing potential challenges, Zynex Inc remains optimistic about its future outlook, aiming to capitalize on market opportunities and drive continued success.

Zynex reports record revenue and growth outlook, driven by innovation

Zynex Inc (ZYXI) delivered strong financial results in Q3 2023, driven by revenue growth, operational efficiency, and strategic product innovations.
The company's focus on noninvasive pain management solutions and commitment to regulatory milestones underscore its growth potential and market positioning.
While facing challenges such as market competition and operational scalability, Zynex's strengths in financial performance and innovation present opportunities for sustained success.

Zynex Inc (ZYXI) reports record revenue and explores strategic alternatives

Zynex Inc (ZYXI) delivered a strong performance in 2023, marked by record revenue, profitability, and operational achievements, positioning the company for continued growth and success.
While facing challenges related to strategic decision-making and operational execution, Zynex remains well-positioned to capitalize on opportunities for revenue expansion, product innovation, and market leadership.
With a focus on financial stability, product diversification, and strategic growth initiatives, Zynex is poised to navigate challenges, leverage opportunities, and drive value for shareholders in the upcoming year.

Zynex Inc reports revenue growth and FDA clearance success

Zynex Inc (ZYXI) demonstrated solid financial performance in Q1 2024, with revenue growth and positive cash flow.
The company's focus on product innovation, sales expansion, and revenue diversification positions it well for future growth.
While facing challenges such as revenue delays and strategic uncertainties, Zynex remains optimistic about its growth prospects and market opportunities.

Zynex Inc reports strong Q2 performance, eyes $200M revenue target

Zynex Inc delivered a strong Q2 2024 performance with revenue growth, improved sales efficiency, and a positive outlook for the year, targeting $200 million in total revenue.
While facing challenges in revenue diversification and sales force refinement, Zynex maintains a solid gross profit margin and a focus on operational excellence.
The company's Monitoring Solutions division shows promise, with ongoing product milestones and plans for FDA submission, indicating future growth potential and market expansion.
Strategic management of challenges and capitalizing on opportunities position Zynex well for sustained growth and profitability in the evolving healthcare market.

Zynex Inc reports strong Q3 performance and eyes growth opportunities

Zynex Inc's Q3 2024 performance reflects revenue growth, profitability, and strategic reinvestment in the business.
While facing challenges in decision-making and operational efficiency, the company is well-positioned for growth.
Opportunities in expanding sales, launching new products, and exploring partnerships pave the way for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Zynex, Inc. (ZYXI) CEO Thomas Sandgaard on Q4 2020 Results - Earnings Call Transcript

Shares of Zynex (NASDAQ:ZYXI) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 44.44% over the past year to $0.05, which missed the estimate of $0.06.

Recap: Zynex Q4 Earnings

ENGLEWOOD, Colo., Feb. 25, 2021 /PRNewswire/ -- 2020 Full Year Revenue increased 76% year over year to $80.1 million Orders increased 96% Net income of $9.1 million; Diluted EPS $0.26 Adjusted EBITDA $13.7 millio 2020 Revenue and Adjusted EBITDA are the highest in Company history 2020...

Zynex Announces 2020 Fourth Quarter and Full Year Earnings

ENGLEWOOD, Colo., Feb. 18, 2021 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics,...

Zynex Schedules 2020 Fourth Quarter and Full-Year Earnings Call

ENGLEWOOD, Colo., Jan. 28, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today...

Zynex Appoints Anna Lucsok as Chief Operating Officer of Zynex Medical

ENGLEWOOD, Colo., Jan. 14, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today...

Zynex Announces Filing of Patent for Sepsis Monitor

ENGLEWOOD, Colo., Jan. 6, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today...

Zynex Announces a Second Utility Patent for Its Blood Volume Monitor

ENGLEWOOD, Colo., Nov. 19, 2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today...

Zynex Ranked 13th in Revenue Growth Among Medical Device Companies

ENGLEWOOD, Colo., Nov. 17, 2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today...

Zynex to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Zynex, Inc. (ZYXI) CEO Thomas Sandgaard on Q3 2020 Results - Earnings Call Transcript

Shares of Zynex (NASDAQ:ZYXI) decreased 2.79% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 33.33% year over year to $0.04, which missed the estimate of $0.05.

Recap: Zynex Q3 Earnings

ENGLEWOOD, Colo., Oct. 27, 2020 /PRNewswire/ -- Revenue increased 69% year over year to $20.0 million Orders increased 96% Net income of $1.3 million; Diluted EPS $0.04 Adjusted EBITDA $2.4 million Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the...

Zynex Announces Third Quarter 2020 Earnings

Shares have been taken down yet again, on a mild guidance decrease. However, order growth has come back strongly and revenues will follow that.

Zynex Has Fallen Way Too Deep

ENGLEWOOD, Colo., Oct. 23, 2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today...

Zynex Appoints Neil Friery as President and Chief Operating Officer of Monitoring Solutions Division

ENGLEWOOD, Colo., Oct. 20, 2020 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics,...

Zynex Schedules 2020 Third Quarter Earnings

The medical technology company's revenue isn't growing as much as hoped.

Why Zynex Stock Is Tanking Today

ENGLEWOOD, Co., Oct. 12, 2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today...

Zynex Announces 96% Year over Year Order Growth

Zynex: 'Electric' Growth And Strong Earnings Keep Us Bullish

A Relative Strength Rating upgrade for Zynex shows improving technical performance. Will it continue?

Stocks With Rising Relative Strength: Zynex

A Relative Strength Rating upgrade for Zynex shows improving technical performance.
The post Zynex Shows Market Leadership With Jump To 82 RS Rating appeared first on Investor's Business Daily.

Zynex Shows Market Leadership With Jump To 82 RS Rating

Magnite

Retail Opportunity Investments

These stocks are much cheaper than they were a few months ago and have great long-term prospects.

Have $3,000? Consider Buying These Small-Cap Stocks

Zynex, Inc. (ZYXI) CEO Thomas Sandgaard on Q2 2020 Results - Earnings Call Transcript

Shares of Zynex (NASDAQ:ZYXI) increased 2.65% in after-market trading after the company reported Q2 results.

Recap: Zynex Q2 Earnings

ENGLEWOOD, Colo., July 28, 2020 /PRNewswire/ -- Zynex, Inc.

Zynex Announces Second Quarter 2020 Earnings

Zynex's (ZYXI) April orders down approximately 35% from the January and February average. This may have impacted its Q2 earnings.

News for Zynex Inc Stock (ZYXI)